Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

By clicking “Accept” you acknowledge and agree that neither ITGR nor third party provider Virtua Research, Inc. (“Virtua) is responsible, or accepts or assumes any responsibility or liability whatsoever for, the content, the data or the technical operation of the Linked Site. Further, by entering the External Site, you also acknowledge and agree that you completely and irrevocably waive any and all rights and claims against ITGR and Virtua and further acknowledge and agree that in no event shall ITGR or Virtua, its officers, employees, directors and agents be liable for any (i) indirect, consequential, incidental, special, compensatory or punitive damages, (ii) damages for loss of income, loss of business profits, business interruption, loss of data or business information, loss of or damage to property, (iii) claims of third parties, or (iv) other pecuniary loss, arising out of or related to this disclaimer or the External Site

By entering the External Site, you further acknowledge and agree that the disclaimer of warranties and limitations of liability set out in this disclaimer shall apply regardless of the causes, circumstances or form of action giving rise to the loss, damage, claim or liability, even if such loss, damage, claim or liability is based upon breach of contract (including, without limitation, a claim of fundamental breach or breach of a fundamental term), tort (including, without limitation, negligence), strict liability or any other legal or equitable theory, and even if ITGR and Virtua are advised of the possibility of the loss, damage, claim or liability. The waiver and release specifically includes, without limitation, any and all rights and claims pertaining to the processing of personal data, including but not limited to any rights under any applicable data protection statute(s).

If in any jurisdiction, any part of this disclaimer is held to be unenforceable by a court of competent jurisdiction, such part of this disclaimer shall be restricted or eliminated to the minimum extent and the remaining disclaimer shall otherwise remain in full force and effect.

Please note the information presented is deemed representative at the time of its original release. Changes in historical information may occur due to adjustments in accounting and reporting standards & procedures.

Non-GAAP Information

In addition to disclosing results determined in accordance with GAAP, ITGR may also disclose certain non-GAAP and pro forma non-GAAP results of operations, including certain ratios, operational and miscellaneous data, as well as net income, diluted earnings per share, operating expenses, and operating income that make certain adjustments or exclude certain charges and gains that are outlined in the schedules included in this website. Management believes that this non-GAAP and pro forma non-GAAP information provides investors with additional information to assess ITGR operating performance by making certain adjustments or excluding costs or gains and assists investors in comparing our operating performance to prior periods. Management uses this non-GAAP and pro forma non-GAAP information, along with GAAP information, in evaluating its historical operating performance. ITGR and Virtua also take no responsibility for third party pricing data provided for informational purposes and certain ratio results formulated from the provided third party pricing data.

The non-GAAP information is not prepared in accordance with GAAP and may not be comparable to non-GAAP information used by other companies. The non-GAAP information should not be viewed as a substitute for, or superior to, other data prepared in accordance with GAAP.

Greatbatch, Inc. Reports 2010 First Quarter Results

April 29 2010

CLARENCE, N.Y., Apr 29, 2010 (BUSINESS WIRE) --Greatbatch, Inc. (NYSE: GB), today announced results for its first quarter ended April 2, 2010:

  • Sales of $132.0 million. While 6% below the prior year were 5% above the sequential quarter.
  • Adjusted operating margin of 11.4% reflecting higher R&D investment.
  • GAAP diluted EPS of $0.24 per share and adjusted diluted EPS of $0.32 per share.
  • Strong cash flows from operations of $21 million.
  • Affirms full year 2010 guidance.

2010 2009 % 2009 %

(Dollars in thousands, except share data)

1st Qtr. 1st Qtr. Change 4th Qtr. Change








GAAP Operating Income (Loss) $ 13,996 $ 14,799 -5% $ (2,287) NA
GAAP Operating Income (Loss) as % of Sales 10.6% 10.6% 0.0% -1.8% 12.4%
Adjusted Operating Income* $ 14,988 $ 17,602 -15% $ 16,422 -9%
Adjusted Operating Income as % of Sales 11.4% 12.6% -1.2% 13.1% -1.7%
GAAP Diluted EPS $ 0.24 $ 0.28 -14% $ (0.07) NA
Adjusted Diluted EPS* $ 0.32 $ 0.41 -22% $ 0.40 -20%

* See Tables A and B at the end of this release for reconciliation of adjusted amounts to GAAP.

CEO Comments

"Our sales results were in line with our expectations and indicative of a good start to the year," stated Thomas J. Hook, president & CEO, Greatbatch, Inc. "We carried the momentum that began in the fourth quarter of last year into 2010, delivering sequential sales growth for the second consecutive quarter. More importantly, our growth was broad-based and was supported by improvement in all of the underlying markets we serve. This improvement, coupled with our strong customer relationships and strategic initiatives, gives us confidence in our previously communicated expectations for the year. We remain committed to our long-term growth and profitability, which we believe will be fueled by our investments in innovative new products and solutions, as well as improved operational efficiencies across our business."

First Quarter Results

Consolidated sales in the first quarter of 2010 were $132.0 million versus the $139.8 million in the comparable 2009 period. This 6% decline from the prior year was due to inventory stocking by our customers in the 2009 period and the underlying conditions in the orthopaedics and energy markets. However, in comparison to the sequential 2009 fourth quarter, sales increased 5% driven by improvements across all of our product lines, including a 17% increase in orthopaedics and an 8% increase in vascular sales.

Gross profit as a percentage of sales for the 2010 first quarter was consistent with the 2009 first quarter of 31.6%, as the benefit from our various consolidation and cost-cutting initiatives was offset by lower production volumes and excess capacity, which was expensed in the current quarter. We expect that our margins will improve throughout 2010 as sales levels increase and we more fully utilize our manufacturing capacity.

Selling, general and administrative expenses of $15.7 million for the first quarter of 2010 were $3.0 million lower than the same period of 2009 due to our various consolidation and cost cutting initiatives, as well as reduced 2010 performance-based compensation of approximately $1.6 million for the quarter compared to the 2009 period.

As expected, net research, development and engineering ("RD&E") costs for the 2010 first quarter of $11.0 million were above the comparable 2009 period of $7.9 million, due to the Company further investing resources in the development of new technologies in order to provide solutions for its customers and ultimately create long-term growth opportunities. Additionally, during the quarter the Company received a lower level of customer cost reimbursements. These cost reimbursements can vary significantly from period to period due to the timing of the achievement of milestones on development projects. Excluding customer cost reimbursements, RD&E was 9.5% of sales for the current quarter compared to 7.5% of sales in the first quarter of 2009. Management anticipates that while cost reimbursements will return to more normal levels, the higher level of RD&E investment will continue for the remainder of 2010, consistent with the Company's long-term growth strategy.

GAAP operating income for the first quarter of 2010 was $14.0 million compared to $14.8 million for the 2009 first quarter. Similarly, adjusted operating income was $15.0 million, or 11.4% of sales, in the first quarter 2010, compared to $17.6 million, or 12.6% of sales, for the comparable 2009 period. Adjusted operating income amounts for the first quarter of 2010 and 2009 exclude the impact of facility consolidation, manufacturing transfer and system integration charges, asset write-down and disposition charges. See Table A at the end of this release for a reconciliation of adjusted operating income amounts to GAAP and the "Use of Non-GAAP Financial Information" section below.

The 2010 first quarter GAAP and adjusted effective tax rates increased to 35%, compared to 31.5% and 32.6%, respectively, for the 2009 period. This increase was primarily due to the expiration of the U.S. R&D tax credit at the end of 2009. Current proposed legislation, if enacted, would reinstate this tax credit retroactive to the beginning of the year.

GAAP diluted EPS for the first quarter 2010 were $0.24 per share compared to $0.28 per share for the first quarter 2009. Similarly, adjusted diluted EPS were $0.32 per share in the first quarter 2010 versus $0.41 for the comparable 2009 period. See Table B at the end of this release for a reconciliation of adjusted diluted EPS amounts to GAAP and the "Use of Non-GAAP Financial Information" section below.

Cash flows from operations for the first quarter of 2010 were approximately $21 million compared to $0.06 million for the 2009 first quarter and $21.5 million for the 2009 fourth quarter. The increase from the prior year first quarter is primarily due to the Company's strategic initiatives designed to improve operational efficiency, which included initiatives to reduce inventory and receivable levels, as well as the timing of payments and lower consolidation and integrations costs. As of April 2, 2010, the Company had $56 million of cash and cash equivalents and approximately $114 million of availability under its revolving line of credit. The Company currently expects that cash generated during 2010 will be used to support capital expenditures and to pay down debt.

CFO Comments

"We are encouraged by our top-line growth and strong cash generation over the last two quarters," commented Thomas J. Mazza, senior vice president & chief financial officer. "During the quarter, we continued to take steps to improve our operating efficiency in order to fund our RD&E investments and we expect our operating margin to improve throughout the remainder of the year as sales increase and we further leverage our manufacturing capacity. We remain confident that our full-year adjusted operating margin will be in-line with our previously stated guidance of 12.0% to 13.5% of sales for 2010."

Product Lines

The following table summarizes the Company's sales by major product lines (in thousands):

2010 2009 % 2009 %

Product Lines

1st Qtr. 1st Qtr. Change 4th Qtr. Change
Greatbatch Medical
CRM/Neuromodulation $76,925 $77,267 0% $75,969 1%
Vascular 8,166 10,733 -24% 7,556 8%
Orthopaedics 29,442 34,083 -14% 25,233 17%
Total Greatbatch Medical 114,533 122,083 -6% 108,758 5%
Electrochem 17,496 17,735 -1% 17,050 3%
Total Sales $132,029 $139,818 -6% $125,808 5%

Greatbatch Medical

CRM and neuromodulation sales remained consistent with the prior year first quarter. Current quarter sales includes the benefit of further adoption of the Company's Q batteries, which empower new device features and reduces the overall size of medical devices. Offsetting these increases was lower feedthrough sales as the first quarter 2009 included the benefit of customer product launches.

First quarter 2010 sales for the vascular product line were $8.2 million, compared to prior year sales of $10.7 million. This decrease was primarily due to lower introducer sales as a result of customer inventory stocking during the first half of 2009 in connection with our on-going introducer litigation. The impact of this inventory stocking began to ease during the first quarter of 2010 as vascular sales increased 8% from the sequential quarter.

Orthopaedics product line sales of $29.4 million for the first quarter 2010 declined from the $34.1 million for the comparable 2009 period due to the uncertain economic and regulatory environment, which caused reduced spending on elective procedures and increased emphasis by our customers on inventory management programs. As expected, the impact of these factors eased further during the current quarter as sales increased 17% over the sequential quarter.


First quarter 2010 sales for the Electrochem business segment were $17.5 million, slightly below the $17.7 million in the first quarter 2009. The decrease from the prior year primarily related to the slowdown in the energy and portable medical markets, which caused customers to reduce inventory levels and push back projects. These conditions continued to ease in the first quarter, but are still expected to be a challenge for the next two quarters.

Financial Guidance

At this time, we are reaffirming the guidance provided at the beginning of the year as follows:

2010 Annual Sales Growth Rates

  • CRM & Neuromodulation: 2% to 5%
  • Vascular: 3% to 7%
  • Orthopaedics: 3% to 7%
  • Electrochem: 0% to 5%

Adjusted Operating Income as % of Sales*: 12.0% - 13.5% of sales for the full year 2010

* Adjusted operating income is GAAP operating income excluding costs associated with plant consolidations and integration of acquisitions of approximately $4.0 million to $6.0 million.

Conference Call

The Company will host a conference call on Thursday April 29, 2010 at 5:00 p.m. Eastern Time to discuss these results. The scheduled conference call will be webcast live and is accessible through the Company's website at www.greatbatch.com. An audio replay will also be available beginning from 8:00 p.m. Eastern Time on April 29, 2010 until May 6, 2010. To access the replay, dial 888-286-8010 (U.S.) or 617-801-6888 (International) and enter the passcode 95822768.

About Greatbatch, Inc.

Greatbatch, Inc. (NYSE: GB) provides top-quality technologies to industries that depend on reliable, long-lasting performance through its brands Greatbatch Medical and Electrochem. Greatbatch Medical develops and manufactures critical technologies used in medical devices for the cardiac rhythm management, neuromodulation, vascular and orthopaedics markets. Electrochem designs and manufactures battery and wireless sensing technologies for high-end niche applications in the energy, military, portable medical, and other markets. Additional information about the Company is available at www.greatbatch.com.

Use of Non-GAAP Financial Information

In addition to our results reported in accordance with GAAP, we provide adjusted operating income and margin, adjusted net income and adjusted earnings per diluted share. These adjusted amounts consist of GAAP amounts excluding the following adjustments to the extent occurring during the period: (i) acquisition-related charges, (ii) facility consolidation, manufacturing transfer and system integration charges, (iii) asset write-down and disposition charges, (iv) litigation charges (v) convertible debt accounting change adjustments and (vi) the income tax (benefit) related to these adjustments. Adjusted earnings per diluted share is calculated by dividing adjusted net income for diluted earnings per share by diluted weighted average shares outstanding. We believe that the presentation of adjusted operating income and margin, adjusted net income and adjusted diluted earnings per share provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.

Forward-Looking Statements

Some of the statements in this press release, including the information provided under the caption "Financial Guidance," and other written and oral statements made from time to time by the Company and its representatives are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, and involve a number of risks and uncertainties. These statements can be identified by terminology such as "may," "will," "should," "could," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," or the negative of these terms or other comparable terminology. These statements are based on the Company's current expectations. The Company's actual results could differ materially from those stated or implied in such forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements include, among others, the following matters affecting the Company: our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement our cost reduction and plant consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate the acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our inability to obtain licenses to key technology; regulatory changes or consolidation in the healthcare industry; global economic factors including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company and other risks and uncertainties described in the Company's Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission. The Company assumes no obligation to update forward-looking information in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

Table A: Operating Income Reconciliation (in thousands):

2010 2009
1st Qtr. 1st Qtr.
Operating income as reported: $ 13,996 $ 14,799
Consolidation costs 320 1,899
Integration expenses 122 863
Asset dispositions & other 550 41
Operating income - adjusted $ 14,988 $ 17,602
Operating margin - adjusted 11.4% 12.6%

Table B: Net Income and Diluted EPS Reconciliation (in thousands, except per share amounts):

2010 2009
1st Qtr. 1st Qtr.
Income before taxes as reported: $ 8,534 $ 9,728
Consolidation costs 320 1,899
Integration expenses 122 863
Asset dispositions & other 550 41
Adjusted income before taxes 9,526 12,531
Convertible debt accounting change 1,914 1,775
Sub-total 11,440 14,306
Adjusted provision for income taxes 4,004 4,666
Adjusted net income $ 7,436 $ 9,640
Adjusted diluted EPS $ 0.32 $ 0.41
Number of shares 23,900 23,900

Note: Adjustments were made based on the adjusted effective tax rate of 35.0% for 2010 and 2009.

(In thousands except per share amounts)
Three months ended
April 2, April 3,
2010 2009
Sales $ 132,029 $ 139,818
Cost of sales 90,365 95,654
Gross profit 41,664 44,164
Operating expenses:
Selling, general and administrative expenses 15,652 18,687
Research, development and engineering costs, net 11,024 7,875
Other operating expense, net 992 2,803
Total operating expenses 27,668 29,365
Operating income 13,996 14,799
Interest expense 5,148 4,889
Interest income (2 ) (25 )
Other expense, net 316 207
Income before provision for income taxes 8,534 9,728
Provision for income taxes 2,987 3,064
Net income $ 5,547 $ 6,664
Earnings per share:
Basic $ 0.24 $ 0.29
Diluted $ 0.24 $ 0.28
Weighted average shares outstanding:
Basic 23,000 22,800
Diluted 23,900 23,900
(In thousands)
As of
ASSETS April 2, January 1,
2010 2010
Current assets:
Cash and cash equivalents $ 56,317 $ 37,864
Accounts receivable, net 81,568 81,488
Inventories 105,924 106,609
Deferred income taxes 14,040 13,896
Prepaid expenses and other current assets 10,607 13,313
Total current assets 268,456 253,170
Property, plant, and equipment, net 148,110 153,601
Intangible assets, net 99,380 102,364
Goodwill 302,778 303,926
Deferred income taxes 1,764 2,458
Other assets 14,777 15,024
Total assets $ 835,265 $ 830,543
Current liabilities:
Accounts payable $ 35,505 $ 34,395
Income taxes payable 1,253 403
Current portion of long-term debt 30,450 30,450
Deferred income taxes 196 -
Accrued expenses and other current liabilities 62,844 67,996
Total current liabilities 130,248 133,244
Long-term debt 261,327 258,972
Deferred income taxes 55,625 54,043
Other long-term liabilities 4,406 4,560
Total liabilities 451,606 450,819
Stockholders' equity:
Preferred stock - -
Common stock 23 23
Additional paid-in capital 293,035 291,926
Treasury stock (635 ) (635 )
Retained earnings 91,809 86,262
Accumulated other comprehensive gain (loss) (573 ) 2,148
Total stockholders' equity 383,659 379,724
Total liabilities and stockholders' equity $ 835,265 $ 830,543

SOURCE: Greatbatch, Inc.

Greatbatch, Inc.
Marco Benedetti, 716-759-5856
Corporate Controller & Treasurer